drugset / Trial / NCT04250636
3BNC117-LS and 10-1074-LS in Viremic HIV-infected Individuals
Phase 1
Completed
6 enrolled
Rockefeller University
National Institute of Allergy and Infectious Diseases (NIAID) · collabUniversity of Pennsylvania · collabWeill Medical College of Cornell University · collab
NaSingle-groupOpen-labelTreatment
Summary
The proposed study is a phase 1, open label, single arm study to evaluate the safety, pharmacokinetics and antiviral activity of single intravenous infusions of 3BNC117-LS and 10-1074-LS, each monoclonal antibody (mAb) dosed at 30 mg/kg in viremic human immunodeficiency virus (HIV)-infected individuals.
Timeline
- Start
- 2020-10-13
- Primary completion
- 2022-01-21
- Completion
- 2022-02-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Teropavimab | Monoclonal antibody | 30 mg/kg | Intravenous |
| Subject | Zinlirvimab | Monoclonal antibody | 30 mg/kg | Intravenous |